Sprott Uranium Miners ETF vs Zoetis Inc — how do they compare? Sprott Uranium Miners ETF trades at $46.43 (market cap $1.87B), while Zoetis Inc trades at $74.42 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 16.1× Sprott Uranium Miners ETF's market cap, and Zoetis Inc pays a 2.9% dividend while Sprott Uranium Miners ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sprott Uranium Miners ETF for 61 Days and Zoetis Inc for 70 Days on average.
| URNM | ZTS | |
|---|---|---|
Market Cap | $1.87B | $30.20B |
Volume | 1,586,926 | 6,175,327 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $83.99 | $147.53 |
52-Week Low | $46.09 | $69.09 |
Typical Hold Time | 61 Days | 70 Days |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Signals from Pluang's Aura AI — not financial advice
URNM (Sprott Uranium Miners ETF) trades at $46.43, down 3.01% today amid bearish technical signals. The ETF shows 13 sell signals versus 0 buy signals across moving averages, with oversold RSI readings suggesting potential near-term stabilization. Recent news highlights uranium's strong fundamentals driven by AI power demand and government nuclear investments, though the sector faces volatility from supply-demand imbalances.
Long-term outlook remains positive given nuclear energy's role in AI infrastructure and global decarbonization. Key risks include uranium price volatility and geopolitical supply constraints. Analyst sentiment leans bullish on uranium's structural deficit, with institutional interest growing in pure-play uranium mining exposure.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →